Protocol to Assess the Severity of Acute Kidney Injury (AKI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00673244|
Recruitment Status : Completed
First Posted : May 7, 2008
Last Update Posted : February 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Acute Kidney Failure||Drug: Furosemide||Not Applicable|
AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.
Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for RRT. Therefore, it is vitally important to know early in the course which patients with AKI are likely to progress to RRT.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Protocol to Assess the Severity of Acute Kidney Injury|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
Other Name: Lasix
- Patients meeting the definition for stage 3 of Acute Kidney injury as defined by the Acute Kidney Injury Network (AKIN-3) system. [ Time Frame: 14 days or discharge (whichever occurs first) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00673244
|United States, District of Columbia|
|George Washington University Hospital|
|Washington, District of Columbia, United States, 20037|
|Principal Investigator:||Lakmir S Chawla, MD||George Washigton University|